Indian API Drug Maker Shasun To Expand Japanese Market
This article was originally published in PharmAsia News
Indian active pharmaceutical ingredient maker Shasun Chemicals and Drugs plans to expand into the Japanese market, announced by Shasun VP Michel Spagnol at a March 3 Tokyo briefing. The company established Japanese subsidiary Shasun Japan last year, and has set sales goal of $7 million for 2009. Shasun looks to expand into the clinical research business and API and drug medium production in Japan. The company also plans to collaborate with Japanese domestic drug makers. (Click here for more - Japanese language
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.